CAMBRIDGE (MASSACHUSETTS) (dpa-AFX) - Vertex Pharmaceuticals Inc. (VRTX) announced the final results from a Phase 2a study of the investigational selective oral JAK3 inhibitor VX-509. The data showed substantial and statistically significant improvements in multiple measurements of rheumatoid arthritis activity.
The 12-week study met its two primary endpoints, defined as a statistically significant improvement in the proportion of people who achieved at least a 20 percent improvement in the signs and symptoms of RA and a statistically significant improvement from baseline in Disease Activity Score 28.
The data from the study will be presented in a poster session on November 8 at the 2011 Annual Meeting for the American College of Rheumatology in Chicago. Based on the Phase 2a data to be presented at ACR, a six-month Phase 2b study of VX-509 in RA is expected to begin in early 2012. T
Copyright RTT News/dpa-AFX